Cheyne Capital Management (UK)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cheyne Capital Management (UK)’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-50,000	Closed	-$407K	–	43
2019 Q1	$407K	Hold	50,000	–	–	0.38%	32
2018 Q4	$404K	Sell	50,000 -50,000	-50%	-$389K	0.38%	33
2018 Q3	$763K	Hold	100,000	–	–	0.45%	35
2018 Q2	$573K	Hold	100,000	–	–	0.41%	32
2018 Q1	$477K	Buy	+100,000	New	+$514K	0.22%	32

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Cheyne Capital Management (UK)'s BCRX Position: Q2 2019 in Review

Cheyne Capital Management (UK) sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 50,000 shares — an estimated $407K sold.

Cheyne Capital Management (UK) first reported a position in BCRX in Q1 2018 and held it in 5 quarters. The position peaked at $763K in Q3 2018. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

Cheyne Capital Management (UK) reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Cheyne Capital Management (UK) sold 50,000 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $407K.
Cheyne Capital Management (UK) first reported a position in BioCryst Pharmaceuticals in Q1 2018 and held it in 5 quarters.
Cheyne Capital Management (UK)'s BioCryst Pharmaceuticals position peaked at $763K in Q3 2018.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Cheyne Capital Management (UK)'s 13F filing for Q2 2019, filed 8 Aug 2019.